---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-041292"
form_type: "8-K"
ticker: "RCEL"
cik: "0001762303"
company_name: "AVITA Medical, Inc."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T18:33:06.865845+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# AVITA Medical Q2 commercial revenue up 42% to $11.7M; raises FY2023 guidance to $51-53M; two FDA approvals

## Summary
- Commercial revenue $11.7M (+42% YoY); net loss $0.41/share vs $0.25 loss in prior year.
- FDA approved RECELL for full-thickness skin defects (June 7) and vitiligo repigmentation (June 16).
- FY2023 revenue guidance raised to $51-53M from prior $49-51M; Q3 guidance $13-14M.
- RECELL GO PMA supplement submitted; FDA decision expected by December 27, 2023.
- Cash $68.8M, no debt; gross margin guided 83-85% for FY2023.

## SEC filing metadata
- accession: 0000950170-23-041292
- form_type: 8-K
- ticker: RCEL
- cik: 0001762303
- company_name: AVITA Medical, Inc.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1762303/000095017023041292/0000950170-23-041292-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1762303/000095017023041292/rcel-20230810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-041292
- JSON: https://secwatch.observer/filing/0000950170-23-041292.json
- Plain text: https://secwatch.observer/filing/0000950170-23-041292.txt

## Key facts
- Earnings Releases
  AVITA Medical, Inc. reported second quarter June 30, 2023 results: revenue $11.7 million, net income $10.4 million, EPS $0.41 per share. Guidance raised.
  - Period: second quarter June 30, 2023
  - Revenue: $11.7 million
  - Net income: $10.4 million
  - EPS: $0.41 per share
  - Guidance: raised
  - Result: reported results
  source text: Commercial revenue of $11.7 million, a 42% increase compared to $8.2 million for the same period in 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1762303/000095017023041292/0000950170-23-041292-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.